The effect of thrombospondin-1 on breast cancer metastasis
- 13 April 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 114 (1) , 85-96
- https://doi.org/10.1007/s10549-008-9992-6
Abstract
Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in these mice at 45, 60 and 90 days of age. Tumor size, areas of necrosis, macrophage infiltration, levels of active and total TGF-β, vessel morphology, and lung and blood metastasis were measured in these mice. Mammary tumors were larger in the TSP-1-null mouse, and vessels were larger, but fewer in number in these tumors. The level of total TGF-β was significantly higher in the Pyt tumors at 90 days of age. Importantly, significantly fewer metastases were observed in the lungs of the TSP-1-null/Pyt mouse. Primary Pyt tumor cells were more migratory than TSP-1-null Pyt tumor cells on collagen. Treatment of Pyt mice with recombinant proteins that contain the type-1 repeats of TSP-1 resulted in decreased primary tumor growth and metastasis. Sequences that are involved in CD36 binding and those required for TGF-β activation mediated the inhibition of primary tumor growth. Thus, TSP-1 in the mammary tumor microenvironment inhibits angiogenesis and tumor growth, but promotes metastasis to the lung in the Pyt transgenic mouse. The ability of TSP-1 to support metastasis correlates with its ability to promote tumor cell migration.Keywords
This publication has 70 references indexed in Scilit:
- Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cellsBiochemical Pharmacology, 2007
- Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical managementJournal of Cellular Biochemistry, 2007
- Thrombospondin-based antiangiogenic therapyMicrovascular Research, 2007
- A Model of Human Tumor Dormancy: An Angiogenic Switch From the Nonangiogenic PhenotypeJNCI Journal of the National Cancer Institute, 2006
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003
- Tamoxifen and Estrogen Effects on TGF-β Formation: Role of Thrombospondin-1, αvβ3, and Integrin-Associated ProteinBiochemical and Biophysical Research Communications, 2001
- Thrombospondin-1 and transforming growth factor-betal promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin systemSurgery, 1997
- Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptorSurgery, 1996
- Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cellsCancer, 1995
- Thrombospondin (TSP) and Transforming Growth Factor β 1 (TGF-β) Promote Human A549 Lung Carcinoma Cell Plasminogen Activator Inhibitor Type 1 (Pal-1) Production and Stimulate Tumor Cell Attachment in VitroBiochemical and Biophysical Research Communications, 1994